Strategies under investigation include combination therapies with other immune modulators (e.g., LAG-3, TIGIT inhibitors), targeted therapies (e.g., EGFR or KRAS inhibitors), and epigenetic modulators that reprogram the tumor microenvironment to be more immunogenic. This evidence concerns the gene TIGIT and neoplasm.